论文信息 - Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. - 字舞流文

Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.

N. Hamerschlak | F. P. Santos | V. Funke | G. Perini | J. Ruiz | B. F. Neto

[1] M. Baccarani,et al. Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP) , 2008 .

[2] S. Marciano,et al. Imatinib-induced fatal acute liver failure. , 2007, World journal of gastroenterology.

[3] K. Bhalla,et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[4] B. Portmann,et al. Imatinib mesylate as a cause of acute liver failure , 2006, American journal of hematology.

[5] M. Boccadoro,et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. , 2006, Haematologica.

[6] J. Ford,et al. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. , 2003, Seminars in hematology.

[7] Stephen Mackinnon,et al. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. , 2003, The New England journal of medicine.